◀ Back to PDK1

PDK1 — PIK3R1

Pathways - manually collected, often from reviews:

• KEGG T cell receptor signaling pathway: PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5 → PDK1 (protein-protein)
• KEGG Fc epsilon RI signaling pathway: PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5 → PDK1 (protein-protein, activation)
• KEGG Neurotrophin signaling pathway: PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5 → PDK1 (protein-protein, compound)
• KEGG Toxoplasmosis: PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5 → PDK1 (protein-protein, compound)
• KEGG Hepatitis C: PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5 → PDK1 (enzyme-enzyme, compound)
• WikiPathways DNA Damage Response (only ATM dependent): PIK3CA/PIK3CB/PIK3CG/PIK3CD/PIK3R1/PIK3R2/PIK3R3/PIK3R4/PIK3R5/PIK3C2A/PIK3C2B/PIK3C2G/PIK3C3 → PDK1 (activation)

Text-mined interactions from Literome

Lu et al., Mol Cancer Res 2010 (Carcinoma...) : These studies show that PDK1 plays a pivotal role in MAPK and PI3K signaling in tumor cells
Mason et al., IDrugs 2010 (Neoplasms) : This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine derived inhibitor BKM-120 ( Novartis AG ), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 ( Pfizer Inc ), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 ( both Pfizer ) and the ability of RO-5323441 ( F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB ) to block tumor growth in vivo